11

CCUURRRRIICCUULLUUMM VVIITTAAEE

0044//1199//22001100

NAME: Sheldon Harrison Preskorn, M.D. CITIZENSHIP: United States of America MEDICAL SCHOOL: University of Kansas, Kansas City, Kansas (M.D., 1974) WEBSITE: www.preskorn.com POSTGRADUATE:

Pathology Residency, University of Kansas Medical Center (UKMC) Kansas City, Kansas, 1973-1975

Rotating Internship, Internal Medicine/Psychiatry UKMC, Kansas City, Kansas, 1975-1976

Psychiatry Residency, Washington University School of Medicine, St. Louis, Missouri, 1976-1978 ACADEMIC APPOINTMENTS:

Professor, Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine (UKSM), Wichita, Kansas, 2007-Present

Professor and Chairman, Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine (UKSM), Wichita, Kansas, 1999-2007

Professor and Vice Chairman, Department of Psychiatry, UKSM, Wichita, Kansas, 1985-1999 Professor of Psychiatry and Pharmacology, Washington University School of Medicine, St. Louis, Missouri, 1984-1985 Associate Professor of Psychiatry and Pharmacology Toxicology & Therapeutics, UKSM, Kansas City, Kansas, 1981-1984 Assistant Professor of Psychiatry and Pharmacology Toxicology & Therapeutics, UKSM, Kansas City, Kansas, 1978-1981 Assistant Instructor in Psychiatry, Washington University School of Medicine, St. Louis, Missouri, 1976-1978

DIRECTORSHIP POSITIONS:

President & CEO, Clinical Research Institute, 2003-Present 201 S. Hillside Wichita, Kansas 67211 & 8911 E. Orme Ste. B Wichita, Kansas 67207 President and Medical Director, Psychiatric Research Institute, 1987-2003

Via Christi Regional Medical Center, Wichita, Kansas Director, Outpatient Clinic Department of Psychiatry,

UKSM, Wichita, Kansas, 1991-1999 Chief, Psychiatry Service,

Wichita Veterans Administration Medical Center, Wichita, Kansas, 1985-1991

LICENSURE: Permanent Kansas Medical License # 4-6344 Permanent Missouri Medical License # 00101337

CONSULTANTSHIP:

Menninger Foundation, Topeka, Kansas, 1992-1998. AWARDS:

Who’s Who in America 2009 America’s Top Psychiatrist, 2008 Foxington Who’s Who Directory of Executives and Professionals, 2000 National Registry of Who’s Who, Life Member, 2000 The Best Doctors in America, 4

th Edition, 1998

22

AWARDS, Continued: American Psychiatric Association, Nancy C.A. Roeske, M.D.,

Certificate of Excellence in Medical Student Education, 1998 National Alliance for the Mentally Ill, Exemplary Psychiatrist Award, 1993 The Mental Health Association in Kansas, 1989 Alliance for Mentally Ill in Sedgwick County, 1988 Research Scientist Development Award (NIMH), 1980-1985 American Academy of Clinical Psychiatry, Clinical Research Award, 1984 University of Kansas College of Health Sciences Research Award, 1983 American Academy of Clinical Psychiatry Annual Research Award, 1982 A.E. Bennett Neuropsychiatric Research Foundation Award, 1978 Roche Laboratory Award for Neuroscience, 1978 Mead-Johnson Award for Overall Excellence in Research, 1978 Walter C. Menninger Neuropsychiatry Award, 1978 Outstanding Young Men of America, 1977 and 1982 KUMC Psychiatric Housestaff Research Award, 1976 KUMC Pathology Housestaff Research Award, 1975 Chester M. Goodwin Award for Neurological Research, 1971 Who's Who in American Colleges and Universities, 1969

FELLOWSHIPS:

Maurice Falk Fellowship, 1975-1978 University of Kansas Research Fellowship, 1971 Wichita State University (WSU) Research Assistantship, 1970 WSU Honors Fellowship, 1969-1970

CERTIFICATION:

Psychiatry plus Geriatric qualifications, American Board of Psychiatry and Neurology, 1997 Diplomat, American Board of Psychiatry and Neurology, 1981 Diplomat, National Board of Medical Examiners, 1975

EDITORIAL BOARDS:

Associate Editor, Journal of Clinical Psychiatry, 2001-Present Associate Editor, Journal of Clinical Psychopharmacology, 2000-Present Contributing Editor, Journal of Psychiatric Practice, (formerly JPPBH) 2000-Present Contributing Editor, Journal of Practical Psychiatry and Behavioral Health, 1995-1999 Preskorn SH: Associate Editor, Current Psychiatry, June 2003-Present American Hospital Formulary Service Drug Information, 1998 Associate Editor, Journal of Clinical Psychiatry, 1978-1988

MAJOR RESEARCH INTEREST:

Psychopharmacology, neuroscience, affective/anxiety disorders GRANTS: Continuous funding since 1978. Supplemental report available. REVIEWER FOR:

American Hospital Formulary Service Drug Information Monographs American Journal of Geriatric Psychiatry American Journal of Primatology American Journal of Psychiatry Annals of Pharmacotherapy Archives of General Psychiatry Biological Psychiatry Bipolar Disorders Clinical Pharmacokinetics CNS Drugs Currents in Affective Illness

33

REVIEWER FOR, Continued: Depression and Anxiety Drug and Aging Journal Drug Evaluations Drugs European Journal of Pharmacology General Hospital Psychiatry Geriatric Agitation Guidelines Geriatric Psychiatry International Journal of Neuropsychopharmacology International Journal of Neuropsychiatry International Journal of Psychiatry in Medicine Journal of Affective Disorders Journal of Clinical Psychiatry Journal of Clinical Psychopharmacology Journal of Neuropsychiatry & Clinical Neurosciences Journal of Pharmaceutical Sciences Journal of Pharmacology and Experimental Therapeutics Journal of Pharmacy Technology Journal of Psychiatric Practice Journal of Psychopharmacology Journal of the American Medical Association Life Sciences Neuropsychopharmacology Pharmacoeconomics Psychiatric Times Psychometrics Psychopharmacology Science Therapeutics Bulletin

REVIEW COMMITTEES: Panel Member, Center for Scientific Review, NIMH Special Emphasis Panel, 1999-Present Panel Member, Center for Scientific Review, NIH Study Sect.-Genetic Sciences, 1999 Member, International Advisory Board for the Guidelines in Depression, 1998–2000 Member, Via Christi Institutional Review Board, 1989-Present Moderator- Faculty, APA. Physician Awareness Program, 1987-1989 Reviewer Canadian Psychiatric Research Foundation Reviewer (Member), Wesley Foundation Scientific Advisory Panel, 1987-1989 Reviewer (ad hoc), VA Merit Rev. Mental Health & Behavioral Science Comm., 1985 Reviewer (ad hoc), Nat'l Inst. Neurological & Communicative DOs & Stroke (NINCDS) study section on Spinal Cord Trauma Centers, 1983 and 1987 Reviewer (ad hoc) National Science Foundation Neuropharmacology Section, 1983-1987 Reviewer (ad hoc), NIMH Psychopharmacological, Biological, and Physical Treatments Research Review Committee (TDA2), 1986 Member, F DA Psychopharmacologic Drugs Advisory Committee, 1982-1986 Reviewer (ad hoc), NIMH Mental Health Behavioral Science Research Review 1984

SOCIETIES: International Society for Affective Disorders, 2001-2002 American Psychopathological Association, Fellow, 1989 American Psychiatric Association, Member, 1979; Fellow, 1987, Distinguished Fellow, 2003 Society of Neuroscience, Member 1978; President 1981-1982; Local Chapter Secretary/Treasurer 1980 American Society of Clinical Pharmacology and Therapeutics, Member, 1979 Society of Biological Psychiatry, Member, 1978 Alpha Omega Alpha, Member, 1973 American Medical Association, Member 1971 Phi Kappa Phi, Member, 1970 Omicron Delta Kappa, President, 1969 WSU Honors Society, Member 1969

44

ORGANIZATIONAL OFFICES: Pharmacy, Therapeutics and Safety Committee, 1998-Present Member, Sedgwick County Task Force on Suicide Prevention, 2001-Present Scientific Advisor, MHA of So. Central Kansas, 2001-2006 NIMH Outreach & Education, 2000-Present Sedgwick County Alliance for Mentally Ill, 1996-Present Advisory Committee, Kansas Alliance for the Mentally Ill, 1993-Present Member, University of Kansas School of Medicine Research Committee, 1992-1994 Member, Board of Directors, Project Awareness for Major Mental Illness, 1990-Present Founding President, Project Awareness for Major Mental Illness, 1990-Present Member, Scientific Program Committee for American Society of Clinical Pharmacology and Therapeutics, 1983-1985 Chairman, KUMC Faculty & Student Affairs Committee, 1983-1984 Member, Governor's Advisory Commission on Mental Health and Retardation Services and Community Mental Health Programs, State of Kansas, 1979-1984 Member, American Psychiatric Association (APA) Program Committee (Nat'l), 1978-1982 Chairman, APA Subcommittee on New Research, 1980-1982 Member, American Psychiatric Association Council-Research & Development,1976-1978 Member, American Psychiatric Association Task Force Tardive Dyskinesia, 1976-1979 Member, Continuing Education Committee for Kansas Psychiatric Society, 1980-1982 Member, KUMC Human Studies Research Committee, 1979-1984 Member, KUMC Peer Utilization Review Committee, 1978-1980 Representative, KUMC Housestaff Association, 1976 Representative, Association of American Medical Colleges, 1971-1973 Treasurer, KUMC Chapter (student) of the KS Medical Society, 1970-1971 President/Administrative/Executive Coordinator, WSU Student Union Activities Board, 1969-1970 Educational/Cultural Coordinator, WSU Student Union Activities Board, 1968-1969 Chairman, Wichita Film Society, 1967-1968

VISITING PROFESSOR/LECTURER: Presented at meetings and/or universities in the following cities on one or more occasions: Foreign Countries Brisbane, Australia Rhodes, Greece Melbourne, Australia Budapest, Hungary Sydney, Australia Jerusalem, Israel Hobart, Australia Cagliari, Italy Vienna, Austria Florence, Italy Bahamas Palermo, Italy Barbados Rome, Italy Brussels, Belgium Venice, Italy Hamilton, Bermuda Kyoto, Japan Rio de Janeiro, Brazil Seoul, Korea San Paulo, Brazil Mexico City, Mexico Edmunton, Canada Acapulco, Mexico Halifax, Canada Monte Carlo, Monaco Hamilton, Canada Amsterdam, Netherlands London, Canada Auckland, New Zealand Montreal, Canada Oslo, Norway Regina, Canada Trondheim, Norway Toronto, Canada Tromso, Norway Saskatchewan, Canada Lisbon, Portugal Vancouver, Canada Las Croabas, Puerto Rico Winnipeg, Canada Ponce, Puerto Rico Beijing, China San Juan, Puerto Rico Guangzhou, China Glascow, Scotland Hanzhou, China Al-Khobar, Saudi Arabia Hong Kong, China Damman, Saudi Arabia Lanzhou, China Jeddah, Saudi Arabia

55

Foreign Countries, Continued: Shanghai, China Riyadh, Saudi Arabia Copenhagen, Denmark Cape Town, South Africa Odense, Denmark Johannesburg, South Africa Alexandria, Egypt Barcelona, Spain Cairo, Egypt Madrid, Spain Oxford, England Linkoping, Sweden London, England Lund, Sweden Cannes, France Stockholm, Sweden Nice, France Basel, Switzerland Paris, France Berne, Switzerland Berlin, Germany Geneva, Switzerland Dresden, Germany Lausanne, Switzerland Frankfurt, Germany Zurich, Switzerland Giessen, Germany Taipei, Taiwan Hamburg, Germany Trinidad Hannover, Germany Anoyla, Turkey Marburg, Germany Istanbul, Turkey Muenster, Germany Dubai, United Arab Emirates Tuebingen, Germany Republic of Singapore Athens, Greece United States of America Baylor University University of California-Sacramento Boston University University of California-San Francisco Bowman University University of California-San Diego Case Western Reserve University University of Colorado Chicago University University of Connecticut-Institute of Living Cleveland Clinic University of Hawaii Columbia University University of Iowa Cornell University University of Kentucky Creighton University University of Louisville Duke University University of Maine East Carolina University University of Miami George Washington University University of Michigan Georgetown University University of Minnesota Harvard University-Beth Israel Hospital University of Mississippi Harvard University-Massachusetts Mental Health Center University of Missouri-Columbia Harvard University-Massachusetts General Hospital University of Missouri-Kansas City Harvard University-McLean Hospital University of Nebraska Henry Ford Hospital-Detroit University of Nevada-Las Vegas Howard University University of Nevada-Reno John Hopkins University University of New Hampshire Loma Linda University University of New Jersey Dental Louisiana State University-Shreveport University of New Mexico Louisiana State University-New Orleans University of North Dakota Loyola University University of Ohio Mayo Clinic University of Oklahoma-Oklahoma City Medical College of Ohio University of Oklahoma-Tulsa Medical College of South Carolina University of Oregon Menninger Foundation University of Pennsylvania New York University University of Pittsburg Northwestern University University of South Dakota Ohio State University University of South Florida Oklahoma Department of Mental Health University of South Carolina-Columbia Purdue University University of Southern Alabama Rush Presbyterian University University of Southern California Southern Illinois University-Springfield University of Tennessee

66

United States of America, Continued: Southwestern Medical College-Dallas University of Texas-Austin St. Louis University University of Texas-Galveston Stanford University University of Utah State University of New York-Albany University of Washington-Seattle State University of New York-Buffalo University of Washington-Spokane State University of New York-Stony Brook University of Vermont Texas Tech University University of Virginia Thomas Jefferson University University of Wisconsin Tufts University University of Wisconsin-Madison Tulane University University of Wisconsin-Milwaukee University of Alabama-Birmingham University of Wisconsin Medical College University of Arizona Vanderbilt University University of Arkansas Washington University University of California-Davis Wayne State University University of California-Irvine Wichita State University University of California-Los Angeles SUMMARIZED PUBLICATIONS: Over 400 scientific and professional publications including over 260 articles, 45 book chapters and 10 books. Principal topics have been basic and clinical psychopharmacology, psychiatric drug development, affective and anxiety disorders, and neuroscience. ITEMIZED PUBLICATIONS:

Journal Articles

(1) Hughes CW, Lewis Jr GA, Preskorn SH. A stereotaxic implant technique for the weanling rat. Behav Res Meth & Instru 1973; 5(3):283-284.

Ref ID: EN 5772

(2) Watanabe I, Preskorn SH. Virus-cell interaction in oligodendroglia, astroglia and phagocyte in progressive multifocal leukoencephalopathy. An electron microscopic study. Acta Neuropathol (Berl) 1976; 36(2):101-115.

Ref ID: EN 3612

(3) Heller-Bettinger I, Kepes JJ, Preskorn SH, Wurster JB. Bilateral altitudinal anopia caused by infarction of the calcarine cortex. Neurology 1976; 26(12):1176-1179.

Ref ID: EN 3611

(4) Cunningham ME, Kishore PR, Rengachary SS, Preskorn SH. Progressive multifocal leukoencephalopathy presenting as focal mass lesion in the brain. Surg Neurol 1977; 8(6):448-450.

Ref ID: EN 3609

(5) Penka WE, Edwards WD, Preskorn SH, Kepes JJ. The deadliest rupture: Idiopathic muscular hypertrophy of the esophagus. J Kansas Med Soc 1977; 78(6):269-275.

(6)

(7) Preskorn SH, Denner LJ. Benzodiazepines and withdrawal psychosis. Report of three cases. JAMA 1977; 237(1):36-38.

(8)

(9) Preskorn SH, Edwards WD, Justesen DR. Retarded tumor growth and greater longevity in mice after fetal irradiation by 2450-MHz microwaves. J Surg Oncol 1978; 10(6):483-492.

(10)

(11) Lewis GA, Preskorn SH, Hughes CW. Altered acetylcholinesterase activity (AChE) and maze performance of developing rats (Rattus norvegicus) following mesencephalic electrical brain stimulation. Physiological Psychology 1978; 6(1):53-56.

(12)

(13) Biggs JT, Preskorn SH, Ziegler V, Rosen S, Meyer D. Dosage schedule and plasma levels of doxepin and desmethyldoxepin. J Clin Psychiatry 1978; 39(10):740-742.

(14)

77

(15) Ziegler V, Biggs JT, Rosen S, Meyer D, Preskorn SH. Imipramine and desipramine plasma levels: relationship to dosage schedule and sampling time. J Clin Psychiatry 1978; 39(8):660-663.

(16)

(17) Preskorn SH, Reveley A. Pseudohypoparathyroidism and capgras syndrome. Br J Psychiatry 1978; 133:34-37.

(18)

(19) Preskorn SH, Abernethy DR, McKnelly Jr. WV. The use of saliva lithium determinations for monitoring lithium therapy. J Clin Psychiatry 1978; 39(10):756-758.

(20)

(21) Preskorn SH, Hartman BK. The effect of tricyclic antidepressants on cerebral fluid dynamics. Biol Psychiatry 1979; 14(2):235-250.

(22) Preskorn SH, Watanabe I. Progressive multifocal leukoencephalopathy: Cerebral mass lesions. Surg Neurol 1979; 12(3):231-234.

(23) Othmer E, Powell B, Piziak VK, Preskorn SH. Prospective use of saliva lithium determinations to monitor lithium therapy. J Clin Psychiatry 1979; 40(12):525-526.

(24) Preskorn SH, Hartman BK. Tricyclic antidepressants: New sites of action. Behav Med 1979; 6:30-33.

(25) Preskorn SH, Hartman BK, Raichle ME, Clark HB. The effect of dibenzazepines (tricyclic antidepressants) on cerebral capillary permeability in the rat in vivo. J Pharmacol Exp Ther 1980; 213(2):313-320.

(26) Preskorn SH, Hartman BK, Raichle ME, Swanson LW, Clark HB. Central adrenergic regulation of cerebral microvascular permeability and blood flow: Pharmacologic evidence. Adv Exp Med Biol 1980; 131:127-138.

(27) Balderessarini R, Cole J, David J, Gardos G, Preskorn SH, Simpson G et al. Tardive dyskinesia: A task force report. Am J Psychiatry 1980; 137(10):1163-1172.

(28) Preskorn SH, Leonard K, Hignite C. Liquid chromatography of amitriptyline and related tricyclic compounds. J Chromotogr 1980; 197:246-250.

(29) Preskorn SH, Hartman BK, Clark HB. Long-term antidepressant treatment: Alterations in cerebral capillary permeability. Psychopharmacology (Berl) 1980; 70(1):1-4.

(30) Preskorn SH, Schwin RL, McKnelly WV. Analgesic abuse and the barbiturate abstinence syndrome. JAMA 1980; 244(4):369-370.

(31) Hughes CW, Preskorn SH. Consideration of physiologic mechanisms in animal models of "sudden death". Omega 1980; 11(2):113-118.

(32) Preskorn SH, Madakasira S. Tricyclic antidepressants: Clinical use of plasma levels. J Kansas Med Soc 1981; 82(3):122-124, 134.

(33) Clark HlB, Hartman BK, Raichle ME, Preskorn SH, Larson KB. Measurement of cerebral vascular extraction fractions in the rat using intracarotid injection techniques. Brain Res 1981; 208(2):311-323.

(34) Hartman BK, Swanson LW, Kaplan GP, Raichle ME, Preskorn SH, Clark HB. Anatomical evidence for central catecholaminergic innervation of the cerebral microvasculature. J Cereb Blood Flow Metab 1981; 1(1):S307-S308.

(35) Preskorn SH, Irwin G, Simpson S, Friesen D. Modulation of cerebral fluid dynamics: Alpha and beta adrenergic mechanisms. J Cereb Blood Flow Metab 1981; 1(S1):S373-S374.

(36) Irwin G.H., Preskorn SH. Simultaneous measurement of brain permeability and blood flow in the rat. J Cereb Blood Flow Metab 1981; 1[suppl 1]:S391-S392.

(37) Preskorn SH, Irwin GH, Simpson S, Friesen D, Rinne J, Jerkovich G. Medical therapies for mood disorders alter the blood-brain barrier. Science 1981; 213(4506):469-471.

(38) Weller RA, Weller EB, Preskorn SH. Clinical response and plasma imipramine levels in prepubertal depressed children. World J Psychosynthesis 1981; 13:9-13.

(39) Glotzbach RK, Preskorn SH. Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology 1982; 78:25-27.

88

(40) Irwin GH, Preskorn SH. A dual label radiotracer technique for the simultaneous measurement of cerebral blood flow and the single-transit cerebral extraction of diffusion-limited compounds in rats. Brain Res 1982; 249(1):23-30.

(41) Preskorn SH, Simpson S. Tricyclic-antidepressant-induced delirium and plasma drug concentration. Am J Psychiatry 1982; 139(6):822-823.

(42) Preskorn SH, Raichle ME, Hartman BK. Antidepressants alter cerebrovascular permeability and metabolic rate in primates. Science 1982; 217(4556):250-252.

(43) Preskorn SH, Irwin HA. Toxicity of tricyclic antidepressants - kinetics, mechanism, intervention: a review. J Clin Psychiatry 1982; 43:151-156.

(44) Clark HB, Hartman BK, Raichle ME, Preskorn SH, Larson KB. An intravenous technique for the measurement of cerebral vascular extraction fraction in e rat. J Cereb Blood Flow Metab 1982; 2(2):187-196.

(45) Preskorn SH, Schreiber M, Hughes CW. Attitudes toward psychiatric consultation: Effect of training. J Psychiatric Treat Eval 1982; 4:313-316.

(46) Weller EB, Weller RA, Preskorn SH, Glotzbach RK. Steady-state plasma imipramine levels in prepubertal depressed children. Am J Psychiatry 1982; 139(4):506-508.

(47) Preskorn SH, Hartman BK, Irwin GH, Hughes CW. Role of the central adrenergic system in mediating amitriptyline-induced alteration in the mammalian blood-brain barrier in vivo. J Pharmacol Exp Ther 1982; 223(2):388-395.

(48) Cantilena JrLR, Irwin G, Preskorn SH, Klassen CD. The effect of diethyldithiocarbamate on brain uptake of cadmium. Toxicol Appl Pharmacol 1982; 63(3):338-343.

(49) Madakasira S, Preskorn SH, Weller R, Pardo M. Single dose prediction of steady state plasma levels of amitriptyline. J Clin Psychopharmacol 1982; 2(2):136-139.

(50) Preskorn SH, Weller E, Weller R. Depression in children: Relationship between plasma imipramine levels and response. J Clin Psychiatry 1982; 43(11):450-453.

(51) Preskorn SH, Glotzbach RK. A liquid chromatographic method for quantitating amitriptyline in brain tissue. Psychopharmacology (Berl) 1982; 78(1):23-24.

(52) Haemmerlie FM, Hughes CW, Preskorn SH. Psychology interns' view of the psychiatric consult. J Psychiatric Treat Eval 1983; 5:277-280.

(53) Preskorn SH. Antidepressant response and plasma concentrations of bupropion. J Clin Psychiatry 1983; 44(5 Pt 2):137-139.

(54) Weller EB, Preskorn SH, Weller RA, Croskell M. Childhood depression: Imipramine levels and response. Psychopharmacol Bull 1983; 19(1):59-62.

(55) Preskorn SH, Hughes CW. Ethanol effects on brain concentrations of amitriptyline and the relationship to psychomotor function. Psychopharmacology (Berl) 1983; 80(3):217-220.

(56) Weller EB, Weller RA, Preskorn SH. Depression in children: Effects of antidepressant therapy. J Kansas Med Soc 1983; 84(3):117-119.

(57) Kent TA, Preskorn SH, Solnick JV, Irwin GH, Swartzman J, Goldberg S et al. Differential effects of central biogenic amines on cerebral blood flow and the blood-brain barrier. J Cereb Blood Flow Metab 1983; 3(1):S228-S229.

(58) Preskorn SH, Weller E, Weller R, Glotzbach E. Plasma levels of impramine and adverse effects in children. Am J Psychiatry 1983; 140(10):1332-1335.

(59) Preskorn SH, Othmer SC. Evaluation of bupropion hydrochloride: The first of a new class of atypical antidepressants. Pharmacotherapy 1984; 4(1):20-34.

(60) Weller R, Preskorn SH. Psychotropic drugs and alcohol: Pharmacokinetic and pharmacodynamic interactions. Psychosomatics 1984; 25(4):301-309.

(61) Ritchie KS, Preskorn SH. Mania induced by metoclopramide: Case report. J Clin Psychiatry 1984; 45(4):180-181.

(62) Preskorn SH, Mac D. The implication of concentration-response studies of tricyclic antidepressants for psychiatric research and practice. Psychiatr Dev 1984; 3:201-222.

(63) Weller E, Weller R, Fristad M, Preskorn SH. The dexamethasone suppression test in hospitalized prepubertal depressed children. Am J Psychiatry 1984; 141(2):290-291.

99

(64) Hughes C, Kent T, Campbell J, Oke A, Croskell H, Preskorn SH. Cerebral blood flow and cerebrovascular permeability in an inescapable shock (learned helplessness) animal model of depression. Pharmacol Biochem & Beh 1984; 21(6):891-894.

(65) Preskorn SH, Othmer SC. Bupropion: A monocyclic antidepressant. J Clin Psychiatry 1984; 2(5):23-26.

(66) Cano SB, Generali JA, Letendre DE, Hastings MT, Preskorn SH. Evaluation of amitriptyline use by internists and psychiatrists. Hosp Formul 1984; 19:1131-1155.

(67) Preskorn SH, Othmer SC, Lai CW, Othmer E. Tricyclic-induced electroencephalogram abnormalities and plasma drug concentrations. J Clin Psychopharmacol 1984; 4(5):262-264.

(68) Preskorn SH, Kent TA, Glotzbach RK, Irwin GH, Solnick JV. Cerebromicrocirculatory defects in animal model of depression. Psychopharmacology 1984; 84:196-199.

(69) Weller E, Weller R, Fristad M, Preskorn SH, Teare M. The dexamethasone suppression test in prepubertal depressed children. J Clin Psychiatry 1985; 46(12):511-513.

(70) Kent T, Preskorn SH. A modified method for the simultaneous determination of regional single-transit brain extraction of diffusion-limited compounds and cerebral blood flow: Utilization of non-invasive measurement of transit time. Brain Res 1985; 335(2):251-255.

(71) Preskorn SH, Mac D. Plasma levels of amitriptyline: Effect of age and sex. J Clin Psychiatry 1985; 46(7):276-277.

(72) Kent TA, Yang R, Croskell H, Preskorn SH. Age effects on the cerebral circulation in the fisher-344 rat. J Cereb Blood Flow Metab 1985; 5 [suppl 1]:S145-S146.

(73) Rubin E, Biggs JT, Preskorn SH. Nortriptyline pharmacokinetics and plasma levels: implications for clinical practice. J Clin Psychiatry 1985; 46(10):418-424.

(74) Weller RA, Weller E, Fristad M, Cantwell M, Preskorn SH. A comparison of the cortisol suppression index and the dexamethasone suppression test in prepubertal children. Am J Psychiatry 1985; 142(11):1370-1372.

(75) Kent T, Nagy G, Oke A, Preskorn SH, Adams R. Effect of CO2 on a brain extracellular space marker and evidence of its neuronal modulation. Brain Res 1985; 342(1):141-144.

(76) Kent T, Preskorn SH, Glotzbach RK, Irwin G. Amitriptyline normalizes tetrabenazine-induced changes in cerebral microcirculation. Biol Psychiatry 1986; 21(5-6):483-491.

(77) Rubin EH, Preskorn SH, Hartman BK. The role of the central adrenergic system in the regulation of the cerebromicrocirculation. Ann N Y Acad Sci 1986; 462:224-231.

(78) Preskorn SH, Weller E, Hughes C, Weller R. Plasma monitoring of tricyclic antidepressants: defining the therapeutic range for imipramine in depressed children. Clin Neuropharmacol 1986; 9[suppl 4]:265-267.

(79) Weller E, Weller R, Fristad M, Cantwell M, Preskorn SH. Dexamethasone suppression test and clinical outcome in prepubertal depressed children. Am J Psychiatry 1986; 143(11):1469-1470.

(80) Preskorn SH. Tricyclic antidepressant plasma level monitoring: An improvement over the dose-response approach. J Clin Psychiatry 1986; 47[suppl 1]:24-30.

(81) Preskorn SH, Weller E, Hughes C, Weller R, Bolte K. Depression in prepubertal children: Dexamethasone nonsuppression predicts differential response to imipramine vs. placebo. Psychopharmacol Bull 1987; 23(1):128-133.

(82) Ziegler D, Hurwitz A, Hassanein R, Kodanaz H, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 1987; 44(5):486-489.

(83) Preskorn SH, Goodwin D. Medical management of the depressed alcoholic patient. Int J Psychiatry Med 1987; 17(2):117-131.

(84) Hughes C, Preskorn SH, Weller E, Weller R, Hassanein R. Imipramine vs. placebo studies of childhood depression: Baseline predictors of response to treatment and factor analysis of presenting symptoms. Psychopharmacol Bull 1988; 24(2):275-279.

(85) Preskorn SH, Weller E, Jerkovich G, Hughes C, Weller R. Depression in children: Concentration-dependent CNS toxicity of tricyclic antidepressants. Psychopharmacol Bull 1988; 24(1):140-142.

(86) Preskorn SH, Dorey RC, Jerkovich GS. Therapeutic drug monitoring of tricyclic antidepressants. Clin Chem 1988; 34(5):822-828.

1100

(87) Fristad M, Weller E, Weller R, Teare M, Preskorn SH. Self-report vs. biological markers in assessment of childhood depression. J Affect Disord 1988; 15:339-345.

(88) Othmer SC, Othmer E, Preskorn SH, Mac D. Differential effect of amitriptyline and bupropion on primary and secondary depression: A pilot study. J Clin Psychiatry 1988; 49:310-312.

(89) Dorey RC, Preskorn SH, Widener P. Results compared for tricyclic antidepressants as assayed by liquid chromatography and enzyme immunoassay. Clin Chem 1988; 34(11):2348-2351.

(90) Bober J, Weller E, Weller R, Tait A, Fristad M, Preskorn SH. Correlation of serum and salivary cortisol levels in prepubertal school-aged children. J Am Acad Child Adolesc Psychiatry 1988; 27(6):748-750.

(91) Preskorn SH, Bupp S, Weller E, Weller R. Plasma levels of imipramine and metabolites in 68 hospitalized children. J Am Acad Child Adolesc Psychiatry 1989; 28(3):373-375.

(92) Preskorn SH. Tricyclic antidepressants: The whys and hows of therapeutic drug monitoring. J Clin Psychiatry 1989; 50[suppl 7]:34-42.

(93) Hughes C, Preskorn SH. Depressive syndromes in children and adolescents: Diagnosis and treatment. Ann Clin Psychiatr 1989; 1(2):109-118.

(94) Preskorn SH, Bupp S, Croskell H, Croskell M. Brattleboro rats exhibit normal PaCO2-induced changes in cerebral microcirculation. Biol Psychiatry 1989; 25(5):648-653.

(95) Preskorn SH, Jerkovich GS, Beber JH, Widener P. Therapeutic drug monitoring of tricyclic antidepressants: A standard of care issue. Psychopharmacol Bull 1989; 25(2):281-284.

(96) Hughes CW, Preskorn SH, Weller E, Weller R, Hassanein R. A descriptive profile of the depressed child. Psychopharmacol Bull 1989; 25(2):232-237.

(97) Yaylayan S, Weller E, Weller R, Fristad M, Preskorn SH. DST status and blood chemistries in prepubertal children. Psychiatry Res 1989; 29(2):215-219.

(98) Preskorn SH, Katz S. Bupropion plasma levels: Intraindividual and interindividual variability. Ann Clin Psychiatr 1989; 1(1):59-61.

(99) Martin R, Preskorn SH. Psychopharmacology - present and future. Psychiatric Annals 1990; 20(11):622.

(100) Preskorn SH. The future and psychopharmacology: Potentials and needs. Psychiatric Annals 1990; 20(11):625-633.

(101) Hughes C, Preskorn SH, Weller E, Weller R, Hassanein R, Tucker S. The effect of concomitant disorders in childhood depression on predicting treatment response. Psychopharmacol Bull 1990; 26(2):235-238.

(102) Hughes C, Preskorn SH, Weller E, Weller R, Hassanein R, Tucker S. Follow-up of adolescents initially treated for prepubertal onset major depressive disorders with imipramine. Psychopharmacol Bull 1990; 26(2):244-248.

(103) Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: Phenomenology, course, risk factors and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 10(2):88-95.

(104) Goldstein E, Kent B, Preskorn SH. Baclofen-Induced delirium: A case report. Ann Clin Psychiatr 1990; 2:223-224.

(105) Preskorn SH, Silkey B, Beber JH, Dorey C. Antidepressant response and plasma concentrations of fluoxetine. Ann Clin Psychiatr 1991; 3(2):147-151.

(106) Bupp S, Preskorn SH. The effect of age on plasma levels of nortriptyline. Ann Clin Psychiatr 1991; 3(1):61-65.

(107) Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: Efficacy, safety and cost effectiveness. J Clin Psychiatry 1991; 52[suppl 6]:23-33.

(108) Preskorn SH. Should bupropion dosage be adjusted based upon therapeutic drug monitoring. Psychopharmacol Bull 1991; 27(4):637-643.

(109) Fristad M, Weller R, Weller E, Teare M, Preskorn SH. Comparison of the parent and child versions of the children's depression inventory (CDI). Ann Clin Psychiatr 1991; 3(4):341-346.

(110) Preskorn SH, Fast GA. Tricyclic antidepressant induced seizures and plasma drug concentration. J Clin Psychiatry 1992; 53(5):160-162.

(111) Preskorn SH, Burke M. Somatic therapy for major depressive disorder: Selection of an antidepressant. J Clin Psychiatry 1992; 53[suppl 9]:5-18.

1111

(112) Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52(5):479-486.

(113) Drevets WC, Videen T, Preskorn SH, Price J, Carmichael S, Raichle M. A functional anatomical study of unipolar depression. J Neurosci 1992; 12(9):3628-3641.

(114) Preskorn SH, Burke M, Fast GA. Therapeutic drug monitoring. Principles and practice. Psychiatric Clinics of North America 1993; 16(3):611-646.

(115) Martin R, Preskorn SH. Special and innovative uses of benzodiazepines: introduction and raison d'etre. Psychiatric Annals 1993; 23(6):299-300.

(116) Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 94 [suppl 5A]:2S-12S.

(117) Horst WD, Preskorn SH. The role of benzodiazepines in the treatment of psychotic disorders. Psychiatr Ann 1993; 23(6):317-324.

(118) Preskorn SH, Fast GA. Beyond signs and symptoms: The case against a mixed anxiety and depression category. J Clin Psychiatry 1993; 54[suppl 1]:24-32.

(119) Preskorn SH. Sudden death and tricyclic antidepressants (TCA): A rare adverse event linked to high TCA plasma levels. Nord J Psychiatry 1993; 47 [suppl 30]:49-55.

(120) Preskorn SH. The revolution in psychiatry. Phi Kappa Phi Journal 1993;22-25.

(121) Ziegler D, Hurwitz A, Preskorn SH, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine: Pharmacokinetic and therapeutic effects. Arch Neurol 1993; 50:825-830.

(122) Preskorn SH. Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. J Clin Psychiatry 1993; 54 [suppl 9]:14-34.

(123) Preskorn SH. Pharmacokinetics of psychotropic agents: Why and how they are relevant to treatment. J Clin Psychiatry 1993; 54[suppl 9]:3-7.

(124) Hughes CW, Preskorn SH. Pharmacokinetics in child/adolescent psychiatric disorders. Psychiatric Annals 1994; 24(2):76-82.

(125) Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14(2):90-98.

(126) Preskorn SH. Targeted pharmacotherapy in depression management: Comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int J Clin Pharmacol 1994; 9[suppl 3]:13-20.

(127) Preskorn SH. Update on antidepressant therapy. J Clin Psychiatry 1994; 55[suppl A]:98-100.

(128) Preskorn SH. Antidepressant drug selection: Criteria and options. J Clin Psychiatry 1994; 55[suppl A]:6-24.

(129) Burke MJ, Silkey B, Preskorn SH. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry 1994; 55(A):42-54, discussion 53-54, 98-100.

(130) Weller R, Kapadia P, Weller E, Fristad M, Lazaroff L, Preskorn SH. Psychopathology in families of children with major depressive disorders. J Affect Disord 1994; 31:247-252.

(131) Cunningham LA. Depression in the medically ill: Choosing an antidepressant. J Clin Psychiatry 1994; 55(9)[suppl A]:90-100.

(132) Preskorn SH, Magnus R. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo finding and their implications for patient care. Psychopharm Bull 1994; 30(2):251-259.

(133) Preskorn SH. Farmacoterapia no tratamento da depressao: farmacocinetica comparative da fluoxetina, paroxetinea e sertraline. Jornal Brasileiro De Psiquiatria 1994; 43(2):69S-75S.

(134) Preskorn SH, Lacey R. Polypharmacy: When is it rational? J Prac Psych and Behav Hlth 1995; 1:92-98.

(135) Preskorn SH. Beyond DSM-IV: What is the cart and what is the horse? Psychiatr Ann 1995; 25(1):53-62.

(136) Preskorn SH, Baker B. Outpatient management of the depressed patient. Dis Mon 1995; 41(2):73-140.

(137) Preskorn SH. Advances in antidepressant pharmacotherapy. Part I. Psych Times 1995;June: 39-41.

1122

(138) Preskorn SH. Should rational drug development in psychiatry target more than one mechanism of action in a single molecule? Int Rev Psychiatry 1995; 7:17-28.

(139) Preskorn SH. Advances in antidepressant pharmacotherapy. Part II. Psych Times 1995; July:14-16.

(140) Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995; 56[suppl 6]:12-21.

(141) Lane R, Baldwin D, Preskorn SH. The SSRIs: Advantages, disadvantages and differences. Journal of Psychopharmacology 1995; 9[suppl 3]:163-178.

(142) Preskorn SH, Lane R. Sertraline 50 mg daily: The optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995; 10(3):129-141.

(143) Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance. Pharmacol Toxicol 1996; 78:203-208.

(144) Preskorn SH. Introduction. Reducing the risk of drug-drug interactions: A goal of rational drug development. J Clin Psychiatry 1996; 57:[suppl 1]:3-6.

(145) Harvey AT, Preskorn SH. Cytochrome P450 Enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharm 1996; 16(4):273-285.

(146) Harvey AT, Preskorn SH. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharm 1996; 16(5):345-355.

(147) Walczak D, Apter JT, Halikas JA, Borison RL, Carman JS, Post GL et al. The oral dose-effect relationship for fluvoxamine: A fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatr 1996; 8(3):139-151.

(148) Preskorn SH. Selection of an antidepressant: Mirtazapine. J Clin Psychiatry 1997; 58[suppl 6]:3-8.

(149) Preskorn SH. Foreward. J Clin Pharmacokinetics 1997; 32(1):1.

(150) Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32[suppl 1]:1-21.

(151) Tremaine L, Wilner K, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 1997; 32[suppl 1]:31-36.

(152) Gardner MJ, Baris BA, Wilner KD, Preskorn SH. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet 1997; 32(1):43-49.

(153) Preskorn SH, Alderman J, Greenblatt DJ, Horst WD. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull 1997; 33(4):659-665.

(154) Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997; 17(4):284-291.

(155) Preskorn SH. Pharmacotherapeutic profile of venlafaxine. Eur Psychiatry 1997; 12[suppl 4]:285S-294S.

(156) Preskorn SH, Harvey AT, Stanga C. Drug interactions and their role in patient care. Current Review of Mood & Anxiety Disorders 1997; 1:203-214.

(157) Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: A case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 1998; 32:432-436.

(158) Preskorn SH, Catterson M. Antidepressants and the elderly: Focus on newer agents. International Journal of Geriatric Psychopharmacology 1998; 1:66-77.

(159) Preskorn SH. Debate resolved: There are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. Journal of Psychopharmacology 1998; 12(3) [suppl B]:S89-S97.

(160) Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51:237-254.

(161) Horst WD, Preskorn SH. The pharmacology and mode of action of venlafaxine. Rev Contemp Pharmacother 1998; 9:293-302.

(162) Preskorn SH. Antidepressant options in primary care. Clinical Cornerstone 1999; 1(4):31-54.

1133

(163) Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants: Cost implications and relevance to clinical practice. Clin Pharmacokinet 1999; 37(2):147-165.

(164) Catterson ML, Martin RL, Preskorn SH. Psychopharmacological drug-drug interactions in the elderly. Clinical Geriatrics 1999; 7(9):46-54.

(165) Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57(5):503-509.

(166) Findling RL, Preskorn SH, Marcus RN, Magnus RD, D'Amico F, Marathe P et al. Nefazodone pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 2000; 39(8):1008-1016.

(167) Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmcol 2001; 21(2):161-166.

(168) Shad M, Marsh C, Preskorn SH. The economic consequences of a drug-drug interaction. J Clin Psychopharmacol 2001; 21(1):119-120.

(169) Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J et al. Efficacy and safety in mirtazapine in depressed patients after SSRI treatment failure: An open-label trial. J Clin Psychiatry 2001; 62(6):413-420.

(170) Werder SF, Preskorn SH. Managing polypharmacy Walking the fine line. Curr Psychiatr 2003; 2(2):24-36.

(171) Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild A, Snavely D et al. Demonstration of the efficacy and safety of a novel substance P(NK1) receptor antagonist (SPA) in major depression. Neuropsychopharmacology 2004; 29(2):385-392.

(172) Preskorn SH, Flockhart DA. 2004 Guide to psychiatric drug interactions. Primary Psychiatry 2004; 11(2):39-60.

(173) Preskorn SH. How drug-drug interactions can impact managed care. Am J Manag Care 2004; 10(6):S186-S198.

(174) Preskorn SH. Why patients may not respond to usual recommended dosages. Curr Psychiatry 2004; 3(8):38-43.

(175) Harvey AT, Flockhart DA, Gorski JC, Greenblatt DJ, Burke M, Werder SF et al. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. J Clin Pharmacol 2004; 44:1173-1184.

(176) Reyes JF, Preskorn SH, Khan AY, Kumar D, Cullen EI, Perdomo CA et al. Concurrent administration of donepezil HCI and risperidone in patients with schizophrenia: Assessment of pharmacokinetic changes and safety following multiple oral doses. BJCP 2004; 58(1):50-57.

(177) Khan AY, Preskorn SH, D'Empaire I. Something in the air. Curr Psychiatr 2004; 3(12):79-88.

(178) Ramadan MI, Khan AY, Preskorn SH. D2-Blockade and possible ziprasidone-induced galactorrhea. J Clin Psychopharm 2005; 20(2):113-114.

(179) Preskorn SH, Silkey B, Shah R, Neff M, Jones TL, Choi J et al. Complexity of medication use in the veterans affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers. J Psychiatr Pract 2005; 11(1):5-15.

(180) Silkey B, Preskorn SH, Shah R. Complexity of medication use in the Veterans Affairs Healthcare System: Part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract 2005; 11(1):16-26.

(181) Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: Role of therapeutic drug monitoring. J Psychiatr Pract 2005; 11(5):1-13.

(182) Khan AY, Preskorn SH, Baker B. Effect of study criteria on recruitment and generalizability of the results. J Clin Psychopharmacol 2005 Jun;25(3):271-5.

(183) Ahsan AY, Carrithers J, Preskorn SH, Wisniewski SR, Lear R, Rush AJ et al. Clinical and demographic factors associated with DSM-IV melancholic depression. Ann Clin Psychiatr. 2006;18(2): 91-99.

(184) Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet 2006. 44(11):1117- 33.

(185) Preskorn, S. H. and D. A. Flockhart (2006). "2006 Guide to Psychiatric Drug Interactions." Primary Psychiatry 13(4): 35-64.

(186) Preskorn, S.H. Pharmacogenomics, Informatics, and Individual Drug Therapy in Psychiatry: Past, Present and Future. J Clin Psychopharmacol 2006. 20:85-94.

(187) Preskorn, S. and S. Werder, Detrimental antidepressant drug-drug interactions: Are they clinically relevant. Neuropsychopharmacology, 2006. 31:1605-1612.

1144

(188) Preskorn SH, Shah R, Neff M, Golbeck A, Choi J. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: Effects with fluoxetine and paroxetine versus sertraline. J Psychiatr Pract 2007; 13(1):5-12.

(189) Preskorn SH, Greenblatt DJ, Flockhart DA, Luo Y, Perloff ES, Harmatz JS et al. Comparison of duloxetine, escitalopram and sertraline effects on cytochrome P45O (CYP) 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007. 27(1):28-34.

(190) Ozdemir V, Williams-Jones B, Graham JE, et al. Asymmetry in scientific method and limits to cross-disciplinary dialogue: Towards a shared language and science policy in pharmacogenomics and human disease genetics. J Investig Med. April 2007. 55(3):130-141.

(191) Preskorn, S.H. A Precautionary Tale in Psychiatry. Psych Times 2007; 24:27-30.

(192) Cascade,E.F., Kalali,A.H., and Preskorn,S.H. EMSAM: The First Year. Psychiatry 2007; 4:19-21.

(193) Khan, A.Y., Preskorn, S.H., and Horst, W.D. Coadministration of Nefazodone and Desipramine: a pharmacokinetic interaction study. Journal of Pakistan Medical Association 2007; 57:230-235

(194) Weiden, P.J., Preskorn, S.H., Fahnestock, P.A., Carpenter, D., Ross, R., and Docherty, J.P. Translating the Psychopharmacology of Antipsychotics to Individualized Treatment for Severe Mental Illness: A Roadmap. J Clin Pharm Ther 2007; 68:1-46.

(195) Preskorn, S. H., Lacey, R.L. Polypharmacy: When is it rational? J Psychiatr Pract 2007; 13: 97-105.

(196) Lincoln, T., Preskorn, S. Out of the Pipeline: Desvenlafaxine Current Psychiatry 2008; 7(6): 89-96.

(197) Preskorn, S. The Development and Use of Modern Psychotherapeutic Medications. Psychiatric Times 2008; 15:1.

(198) Preskorn, S.H., Baker, et al. "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-mythyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder." J Clin Psychopharmacol 2008; 28(6): 631-7.

(199) Lincoln, J., Preskorn, SH. Polydrug regimen: When it becomes irrational and how to simplify it in systematic manner. Current Psychiatry 2008; In Press.

(200) Preskorn, S.H., Nichols, A., Paul, J., Patroneva, A., Helzner, E., Guico-Pabia, C. Effect of Desvenlafaxine on the Cytochrome P450 2D6 Enzyme System. J Psychiatr Pract. 2008; 14(6): 368-378.

(201) Gandelman, K., Alderman, J., Glue, P., Lombardo, I., LaBadie, R.R., Versavel, M., Preskorn, S.H. The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption. J Clin Psychiatry. 2009; 70(1):58-62.

(202) Preskorn, S.H., Patroneva, A., Silman, H., Pederson, R., Isler, J.A., Burczynski, M., Ahmed, S., Paul, J., Nichols, A.I., A Comparison of the Pharmacokinetics of Venlafaxine Extended Release and Desvenlafaxine Succinate in Extensive and Poor Cytochrome P450 2D6 Metabolizers. J Clin Psychopharmacol 2009; 29 (1): 39-43.

(203) Warden D, Rush AJ, Wisniewski SR, Lesser IM, Kornstein SG, Balasubramain GK, Thase ME, Preskorn SH, et al., What predicts attrition in second step medication treatments for depression?: a STAR*D Report. Int J Neuropsychopharmacol, 2009. 12(4): p. 459-73

(204) Preskorn SH. A roadmap to key pharmacologic principles in using antipsychotics: application in clinical practice [Academic Highlights]. J Clin Psychiatry. 2009; 70(4):593-600

(205) Nichols AI, Lobello K, Guico-Pabia CJ, Paul J, Preskorn SH. Venlafaxine Metabolism as a Marker of Cytochrome P450 Enzyme 2D6 Metabolizer Status. J Clin Psychopharmacol 2009;29:383-386

(206) Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Ninan PT. CYP2D6 Phenotype Predicts Antidepressant Efficacy of Venlafaxine. J Clin Psychiatry 2009; in press

(207) Ereshefsky L, Culpepper L, Preskorn SH. The use of Pharmacotherapy for Depression: The Importance of Drug-Drug Interactions. Cli Symposia 2009;59(1)

(208) Chapel S, Hutmacher MM, Haig G, Bockbrader H, de Greef R, Preskorn SH, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol. 2009;49:1297-1308.

(209) Preskorn SH, Flockhart D. 2010 Guide to Psychiatric Drug Interactions, Primary Psychiatry. 2009;16(12):45-74

(210) Shelton RC, Hollon SD, Wisniewski SR, et al. Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report. CNS Spectr 2009;14(9):487-98

1155

(211) Khan A, Catterson ML, Preskorn S. Double-Blind Crossover Study of Mirtazapine, Amitriptyline and Placebo in Patients with Major Depressive Disorder. Directions in Psychiatry 2009;29(29(SR1)):125-30

(212) Lincoln J, Preskorn S. Asenapine for schizophrenia and bipolar I disorder. Curr Psychiatry 2009;8(12):75-85

(213) Chen ML, Shah VP, Ganes D, et al. Challenges and Opportunities in Establishing Scientific and Regulatory Standards for Assuring Therapeutic Equivalence of Modified Release Products: Workshop Summary Report. Eur J Pharm Sci 2010; in press.

(214) Lincoln J, Stewart M, Preskorn S. How Sequential Studies Inform Drug Development: Evaluating the Effect of Food Intake on Optimal Bioavailability of Ziprasidone. J Psych Prac 2010;16(2):103-14.

(215) Lobello K, Preskorn S, Guico-Pabia CJ, et al. Cytochrome P450 2D6 Phenotype Predicts Antidepressant Efficacy of Venlafaxine: A Secondary Analysis of 4 Studies in Major Depressive Disorder. J Clin Psychiatry 2010; in press

Columns:

(1) Preskorn SH. Psychiatry: Into the 21st century. J Prac Psych and Behav Hlth 1995; 1(2):130-131.

(2) Preskorn SH. Advances in psychiatry through genes, molecules and images. J Prac Psych and Behav Hlth 1995; 1(3):193-195.

(3) Preskorn SH. What is the message in the alphabet soup of cytochrome P450 enzymes? J Prac Psych and Behav Hlth 1995; 1:237-240.

(4) Preskorn SH. Why did Terry fall off the dose-response curve? J Prac Psych and Behav Hlth 1996; 2(1):39-43.

(5) Preskorn SH. Have you phenotyped your patient lately? J Prac Psych and Behav Hlth 1996; 2(2):115-117.

(6) Preskorn SH. To monitor or not to monitor? J Prac Psych and Behav Hlth 1996; 2(3):172-175.

(7) Preskorn SH. A dangerous idea. J Prac Psych and Behav Hlth 1996; 2(4):231-234.

(8) Preskorn SH. To monitor or not to monitor, II: The glass is more than half full. J Prac Psych and Behav Hlth 1996; 2(5):307-310.

(9) Preskorn SH. If lack of concentration didn't cause the fall, what did? J Prac Psych and Behav Hlth 1996; 2(6):364-367.

(10) Preskorn SH. Let the data speak to you. J Prac Psych and Behav Hlth 1997; 3(1):45-48.

(11) Preskorn SH. Do you believe in magic? J Prac Psych and Behav Hlth 1997; 3(2):99-103.

(12) Preskorn SH. Patients don't fail treatments, treatments fail patients. J Prac Psych and Behav Hlth 1997; 3(3):165-168.

(13) Preskorn SH. The appearance of knowledge. J Prac Psych and Behav Hlth 1997; 3(4):233-238.

(14) Preskorn SH. I don't see 'em. J Prac Psych and Behav Hlth 1997; 3(5):302-307.

(15) Preskorn SH. Pandora's box: Pregnancy and antidepressants. J Prac Psych and Behav Hlth 1997; 3(6):363-365.

(16) Preskorn SH. Do you feel lucky? J Prac Psych and Behav Hlth 1998; 4(1):37-40.

(17) Preskorn SH. Marooned: Only one choice. J Prac Psych and Behav Hlth 1998; 4(2):110-114.

(18) Preskorn SH. 11.2 billion dollars: Is it worth it? J Prac Psych and Behav Hlth 1998; 4(3):163-168.

(19) Preskorn SH. A message from Titanic. J Prac Psych and Behav Hlth 1998; 4(4):236-242.

(20) Preskorn SH. Sweetness. J Prac Psych and Behav Hlth 1998; 4(5):304-308.

(21) Preskorn SH. What happened to Tommy? J Prac Psych and Behav Hlth 1998; 4(6):363-367.

(22) Preskorn SH. The slippery slide. J Prac Psych and Behav Hlth 1999; 5(1):50-55.

(23) Preskorn SH. Finding the signal through the noise: The use of surrogate markers. J Prac Psych and Behav Hlth 1999; 5(2):104-109.

(24) Preskorn SH. A tale of two patients. J Prac Psych and Behav Hlth 1999; 5(3):160-164.

(25) Preskorn SH. Defining "is". J Prac Psych and Behav Hlth 1999; 5(4):224-228.

(26) Preskorn SH. De-spinning in vitro data. J Prac Psych and Behav Hlth 1999; 5(5):283-287.

(27) Preskorn SH. Two in one: The venlafaxine story. J Prac Psych and Behav Hlth 1999; 5(6):346-350.

1166

(28) Preskorn SH. Bupropion: What mechanism of action? J Prac Psych and Behav Hlth 2000; 6(1):39-44.

(29) Preskorn SH. Imipramine, mirtazapine, and nefazodone: Multiple targets. J Prac Psych and Behav Hlth 2000; 6(2):97-102.

(30) Preskorn SH. The adverse effect of the selective serotonin reuptake inhibitors: Relationship to in vitro pharmacology. J Psychiatr Pract 2000; 6(3):218-223.

(31) Preskorn SH. The relative adverse effect profile of non-SSRI antidepressants: Relationship to in vitro pharmacology. J Psychiatr Pract 2000; 6(4):218-223.

(32) Preskorn SH. The human genome project and modern drug development in psychiatry. J Psychiatr Pract 2000; 6(5):272-276.

(33) Preskorn SH. The stages of drug development and the human genome project: Drug discovery. J Psychiatr Pract 2000; 6(6):341-344.

(34) Preskorn SH, Silkey B. Multiple medications, multiple considerations. J Psychiatr Pract 2001; 7(1):48-52.

(35) Preskorn SH. The human genome project and drug discovery in psychiatry: Identifying novel targets. J Psychiatr Pract 2001; 7(2):133-140.

(36) Preskorn SH. Antipsychotic drug development in the pre-human-genome era: A full circle. J Psychiatr Pract 2001; 7(3):209-213.

(37) Preskorn SH. Drug discovery in psychiatry: Drilling down on the target of interest. J Psychiatr Pract 2001; 7(4):267-272.

(38) Preskorn SH. Drug development in psychiatry and the human genome project: The explosion in knowledge and potential targets. J Psychiatr Pract 2001; 7(5):336-340.

(39) Preskorn SH. Drug development in psychiatry and genomics: From E. coli to man. J Psychiatr Pract 2001; 7(6):415-419.

(40) Preskorn SH. Drug approvals and withdrawals over the last 60 years. J Psychiatr Pract 2002; 7(8):41-50.

(41) Preskorn SH, Silkey B, Jones TL. Physician perceptions of drug-drug interactions and how to avoid them. J Psychiatr Pract 2002; 8(2):112-115.

(42) Preskorn SH, Baker B. The overlap of DSM-IV syndromes: Potential implications for the practice of polypsychopharmacology, psychiatric drug development and the human genome project. J Psychiatr Pract 2002; 8(3):170-177.

(43) Preskorn SH. Fatal drug-drug interactions as a differential consideration in apparent suicides. J Psychiatr Pract 2002; 8(4):233-238.

(44) Preskorn SH. Clinical pharmacology case conference: A suicide attempt? J Psychiatr Pract 2002; 8(5):306-310.

(45) Preskorn SH. Polypharmacy in a patient with refractory major depression: Part I: The case. J Psychiatr Pract 2002; 8(6):370-376.

(46) Preskorn SH. Polypharmacy in a case of refractory major depression: Part II: Implications for clinical management. J Psychiatr Pract 2003; 9(1):71-78.

(47) Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). J Psychiatr Pract 2003; 9(2):150-158.

(48) Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). J Psychiatr Pract 2003; 9(3):228-236.

(49) Preskorn SH. Relating clinical trials to Psychiatric Practice: Part I: The case of a 13-year old on Aripiprazole and fluoxetine. J Psychiatr Pract 2003; 9(4):307-313.

(50) Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions. J Psychiatr Pract 3 A.D.; 10(3):177-181.

(51) Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions (Part II). J Psychiatr Pract 2004;10(3):177-81.

(52) Preskorn SH. Reboxetine: A selective norepinephrine reuptake pump inhibitor. J Psychiatr Pract 2004; 10(1):57-63.

(53) Preskorn SH. Milnacipran: A dual norepinephrine and serotonin reuptake pump inhibitor. J Psychiatr Pract 2004; 10(2):119-126.

1177

(54) Preskorn SH. The recommended dose range: How is it established and why would it ever be exceeded. J Psychiatr Pract 2004; 10(4):249-254.

(55) Preskorn SH. Tianeptine: A facilitator of the reuptake of serotonin and norepinephrine as an antidepressant. J Psychiatr Pract 2004; 10(5):323-330.

(56) Preskorn SH. Duloxetine. J Psychiatr Pract 2004; 10(6):375-385.

(57) Preskorn SH. Multiple medication Use in patients seen in the Veterans Affairs Healthcare System: So what? J Psychiatr Pract 2005; 11(1):46-50.

(58) Preskorn SH. Drug-Drug interactions: Proof of relevance. J Psychiatr Pract 2005; 11(2):116-122.

(59) Preskorn SH. Drug-Drug Interactions: Proof of relevance (Part II): Cause of tolerability problems or noncompliance. J Psychiatr Pract 2005;11(6):397-401.

(60) Preskorn SH. The difference between the formal and the functional dose: The case of the patient of thioridazine and fluvoxamine. J Psychiatr Pract 2005; 11(3):192-196.

(61) Preskorn SH. Clinical application of the concept of relative potency: An example involving chlorpromazine and haloperidol. J Psychiatr Pract 2005; 11(4):258-261.

(62) Preskorn SH. Comments on the role of therapeutic drug monitoring for clozapine. J Psych Pract 2005; 11(5):340-343.

(63) Preskorn SH. Psychopharmacology and psychotherapy: what's the connection. J Psychiatr Pract 2006; 12(1):41-45.

(64) Preskorn SH. Patient with bipolar disorder and familial QT prolongation: What to do? J Psychiatr Pract 2006;12(2):109-12.

(65) Preskorn SH. Why the transdermal delivery of selegiline obviates the need for a dietary restriction on tyramine. J Psychiatr Pract 2006;12(3):168-72.

(66) Preskorn SH. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I. J Psychiatr Pract 2006;12(4):244-9.

(67) Preskorn SH, Borges-Gonzalez S, Flockhart DA. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II. J Psychiatr Pract 2006; 12(5):312-316.

(68) Preskorn SH. Drugs are an acquired source of biological variance among patients. J Psychiatr Pract 2006; 12(6):391-396.

(69) Preskorn, SH. Mania in a Case of Polypsychopharmacology: Pharmacodynamic and Pharmacokinetic Considerations - Do You Believe in Magic? J Psychiatr Pract 2007, 13:178-183.

(70) Preskorn, SH. The Evolution of Antipsychotic Drug Therapy: Reserpine, Chlorpromazine, and Haloperidol. J Psychiatr Pract 2007, 13:253-257.

(71) Preskorn, S., Clinical relevance of relative receptor binding affinity: Quetiapine and ziprasidone as examples. J Psychiatr Pract. 2007. 13(6): p.393-398.

(72) Preskorn, S. H. Neuroleptic Malignant Syndrome Resulting From a Complex Drug-Drug Interaction: "I Don't See 'Em!" J Psychiatr Pract.2007, 13(5): 328-333.

(73) Preskorn, SH. Flat dose-response curves for efficacy: what do they mean to the clinician? J Psychiatr Pract 2008, 14(4): 232-6.

(74) Preskorn, SH. Multiple Medication Use Presenting as Parkinson's Dementia Complex: A Message from Titanic. J Psychiatr Pract 2008, 14(1): 45-54.

(75) Preskorn, SH. Deconstructing a medication regimen. J Psychiatr Pract 2008, 14(2): 114-8.

(76) Preskorn, SH. How multiple medication use evolves and the importance of therapeutic trials: the slippery slide. J Psychiatr Pract 2008, 14(3): 170-5.

(77) Preskorn, SH. Practical Application of Therapeutic Drug Monitoring: A Tale of Two Patients. J Psychiatr Pract 2008, 14(5): 301-306.

(78) Preskorn, SH. Results of the STAR*D Study: Implications for Clinicians and Drug Developers. J Psychiatr Pract 2009, 15(1): 45-49.

(79) Preskorn SH. Patients who do not respond to the "usual" dose: why Terry fell off the dose-response curve. J Psychiatr Pract 2009;15(6):460-6

1188

(80) Preskorn, SH., Drevets, WC. Neuroscience Basis of Clinical Depression: Implications for Future Antidepressant Drug Development. J Psychiatr Pract 2009, 15(2): 125-132

(81) Preskorn, SH. Treatment Options for the Patient Who Does Not Respond Well to Initial Antidepressant Therapy. J Psychiatr Pract 2009, 15(3): 202-210.

(82) Preskorn, SH. How and Why Study Designs Affect the Nature and Validity of Study Results: Appearance Versus True Knowledge. Part 1. J Psychiatr Pract 2009, 15(4): 306-310.

(83) Preskorn, S.H., How and why study designs affect the nature and validity of study results: appearance versus true knowledge. Part II. J Psychiatr Pract, 2009. 15(5): p. 402-7.

(84) Preskorn SH. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters. J Psychiatr Pract, 2010;16(1):46-9.

Book Chapters

(1) Hartman BK, Swanson LW, Raichle ME, Clark HB, Preskorn SH. Evidence for central adrenergic regulation of cerebral vascular permeability and blood flow. In: Usdin E, Kopin IJ, Barchas JD, editors. Basic and clinical frontiers of catecholamine research. New York: Pergammon Press, 1979: 450-453.

(2) Hartman B, Preskorn SH, Raichle M, Swanson L, Clark B. The effect of tricyclic antidepressants on cerebral capillary permeability: An action on a fundamental cerebral homeostatic mechanism. In: Mendels J, editor. Psychobiology of Affective Disorders. Philadelphia: Karger, 1979: 25-48.

(3) Hartman BK, Swanson LW, Raichle ME, Preskorn SH, Clark HB. Central adrenergic regulation of cerebral microvascular permeability and blood flow; anatomic and physiologic evidence. In: Eisenberg HM, Suddith RL, editors. The Cerebral Microvasculature. Unknown: Plenum Publishing Corporation, 1980: 113-126.

(4) Preskorn SH, Hartman B. Cerebrovascular effects of antidepressants: basic and clinical implications. In: Usdin U, Eckert U, Forest U, editors. Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies. Elsevier North Holland, Inc., 1980: 95-98.

(5) Preskorn SH. Tardive dyskinesia and related neuroleptic-induced disorders. In: Helzer J, Martin R, Guze S, editors. Milliken Series in Psychiatry. St. Louis: Milliken, 1980.

(6) Goodwin DW, Preskorn SH. Factors affecting the biphasic concentration: effect relationships of tricyclic antidepressants. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O, editors. Clinical Pharmacology in Psychiatry. Macmillan Publishers LTD, 1981: 297-306.

(7) Goodwin DW, Preskorn SH. DSM-III and pharmacotherapy. In: Turner S, Hersen M, editors. Adult Psychopathology: A Social Work Perspective. New York, NY: John Wiley & Sons, 1982: 453-465.

(8) Preskorn SH. Clinical value of plasma monitoring of antidepressants. In: Ayd FJ, Jr., Taylor IJ, Taylor BT, editors. Affective Disorders Reassessed: 1983. Baltimore: Ayd Medical Communications, 1983: 100-114.

(9) Preskorn SH. Plasma monitoring of antidepressants. In: Berner P, editor. Proceedings of the VII World Congress of Psychiatry. New York: Plenum Press, 1983.

(10) Preskorn SH, Kent TA. Mechanisms and interventions in tricyclic antidepressant overdoses. In: Stancer HC, Garfinkel PE, Rakoff VM, editors. Guidelines for the Use of Psychotropic Drugs. New York: Spectrum Publications Inc., 1984: 63-75.

(11) Hughes C, Preskorn SH, Adams R, Kent T. Etiology of schizophrenia and affective disorders: Neurobiological. In: Cavenar JO, editor. Psychiatry. Philadelphia: Lippincott, 1985: 1-16.

(12) Hughes CW, Preskorn SH, Adams RN, Kent TA. Neurobiological etiology of schizophrenia and affective disorders (1998). In: Michels R, Cavenar JO, Bridie HK, Cooper AM, Guse SB, Judd LL et al., editors. Psychiatry. New York: J.B. Lippincott, 1988: 1-16.

(13) Preskorn SH, Gold M, Extein I. Drug level monitoring in psychiatry. In: Gold MS, editor. Diagnostic and Laboratory Testing in Psychiatry. New York: Plenum Press, 1986: 131-154.

(14) Preskorn SH. Childhood affective disorders. In: Buckalew J, editor. National Depressive and Manic Depressive Association Educational Series. Dallas: NDMDA, 1986.

(15) Preskorn SH. Treatment of tricyclic-resistant depression: The role of tricyclic antidepressant plasma level monitoring. In: Extein IL, editor. Role of Plasma Level Monitoring. Washington D.C.: APA Press, 1989: 3-25.

1199

(16) Preskorn SH. Therapeutic drug monitoring of tricyclic antidepressants: a means of avoiding toxicity. In: Dahl S, Graham L, editors. Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality. Heidelberg: Springer-Verlag, 1989: 237-243.

(17) Preskorn SH, Weller E, Hughes C, Weller R. Depression in children: defining therapeutic range for imipramine. In: Lerer B, Gershon S, editors. New Direction in Affective Disorders. New York, NY: Springer-Verlag, 2000.

(18) Preskorn SH. Antidepressant drug use in pediatric and adolescent patients with affective disorder. In: Amsterdam JD, editor. Pharmacotherapy of depression. New York: Marcel Dekker, Inc., 1996: 321-335.

(19) Preskorn SH, Goodwin WG, Erickson H. DSM-III-R and pharmacotherapy. In: Hersen M, Turner S, editors. Adult Psychopathology and Diagnosis. New York: John Wiley and Sons, Inc., 1991: 482-499.

(20) Preskorn SH, Hughes CW, Bupp SJ. Neurobiological etiology of schizophrenia and effective disorders (revised). In: Michell R, Cooper AM, Guze SB, Judd LL, Kierman GL, Solnit AJ et al., editors. Psychiatry. Philadelphia: Lippincott, 1992: 1-23.

(21) Preskorn SH. Serotonin receptor subtypes and their implications for psychiatric disorders. Hagerman RJ, McKenzie P, editors. International Fragile X Conference Proceedings , 179-194. 1992. Dillon, CO., Sprectra Publishing Co.

(22) Fast GA, Preskorn SH. Therapeutic drug monitoring. In: Dunner DL, editor. Current Psychiatric Therapy. Philadelphia: W.B.Saunders, 1993: 529-534.

(23) Preskorn SH. Dose-effect and concentration-effect relationships with new antidepressants. In: Gram LF, Balant LP, Meltzor HY, Dahl SG, editors. Clinical Pharmacology in Psychiatry. Heidelberg: Springer-Verlag, 1993: 174-189.

(24) Preskorn SH, Burke M, Fast GA. Therapeutic drug monitoring. Principals and practice. Psychiatric Clinics of North America 1993; 16(3):611-646.

(25) Martin R, Preskorn SH. The use of the laboratory in psychiatry. In: Winokur G, Clayton PJ, editors. Medical Basis of Psychiatry. St. Louis, MO: W. B. Saunders Company, 1994: 493-509.

(26) Burke M, Preskorn SH. Short-term treatment of mood disorders with standard antidepressants. In: Bloom FE, Kupfer D, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995: 1053-1065.

(27) Preskorn SH. Psychopharmacology. In: Simpson GM, editor. Manual of Psychiatric Disorders. New York: Impact Communications, 1995: 160-211.

(28) Preskorn SH. The importance of pharmacodynamic and pharmacokinetic considerations in the selection of antidepressant therapy for the elderly. In: Vellas BJ, Albarede L, Garry PJ, editors. Mood and Cognitive Disorders (Facts and Research in Gerontology Journal, 1995 [suppl]. New York, NY: Springer Publisher, 536 Broadway, 1995: 187-204.

(29) Preskorn SH. Selection d'un traitement pharmacologique chez le sujet deprime. In: Vellas P, Albarede JL, Garry PJ, editors. L'Annee Gerontologique. Paris: Serdi, 1995: 372-373.

(30) Preskorn SH, Harvey AT, Stanga C. Drug interactions and their role in patient care. Current Review of Mood & Anxiety Disorders 1997; 1:203-214.

(31) Horst W, Preskorn SH. Intracellular and intercellular principles of the pharmacotherapy of patients with neuropsychiatric disorders. In: Yudofsky S, Hales R, editors. Neuropsychiatry. Washington DC: American Psychiatric Press, Inc., 1997: 55-75.

(32) Preskorn SH. Foreword. In: Knesper DJ, Riba MB, Schwenk TL, editors. Primary Care Psychiatry. Philadelphia: W.B. Saunders, 1997.

(33) Catterson M, Preskorn SH, Martin R. Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. In: Martin R, editor. Geriatric Psychiatry: What's New with the Old? In: The Psychiatric Clinics of North America. Philadelphia: W.B. Saunders Co., 1997: 205-218.

(34) Preskorn SH. Recent dose-effect studies regarding antidepressants. In: Balant LP, Benitez J, Dahl SG, Gram LF, Pinder RM, Potter WZ, editors. European Cooperation in the Field of Scientific and Technical Research. Belguim: European Commission, 1998: 45-61.

(35) Preskorn SH, Harvey AT. Cytochrome P450 enzymes and psychopharmacology. In: Watson SJ, editor. Fourth Generation of Progress . 1998.

(36) Shad MU, Preskorn SH. Antidepressants. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic Drug Interactions. Philadelphia: Lippincott, Williams & Wilkins, 2000: 563-577.

(37) Preskorn SH. Methodological issues in psychopharmacogenetics. In: Lerer B, editor. Pharmacogenetics of Psychotropic Drugs. NY: Cambridge University, 2002: 57.

2200

(38) Preskorn SH. Mood disorders method of. In: Rakel RE, Bope ET, editors. Conn's Current Therapy. Philadelphia: Saunders (Elsevier Science), 2003: 1196-1204.

(39) Khan AY, Preskorn SH. Pharmacokinetic principles and drug interactions. Handbook of medical psychiatry. 2003: 945-944.

(40) Preskorn SH, Catterson ML. General principles of pharmacokinetics. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, present and future. Heidelberg: Springer-Verlag, 2004: 35-86.

(41) Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, Present and Future. Heidelberg: Springer-Verlag, 2004: 87-114.

(42) Preskorn SH, Ross R. Overview of currently available antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, Present and Future. Heidelberg: Springer-Verlag, 2004: 171-183.

(43) Preskorn SH, Ross R, Stanga CY. Selective serotonin reuptake inhibitors. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, Present and Future. Heidelberg: Springer-Verlag, 2004: 241-262.

(44) Preskorn SH, Ross R. Other antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, Present and Future. Heidelberg: Springer-Verlag, 2004: 263-324.

(45) Preskorn SH. Role of pharmacogenetics/pharmacogenomics in the development of new antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, Present and Future. Heidelberg: Springer-Verlag, 2004: 583-607.

(46) D'Empaire I, Preskorn SH. Use of Laboratory Assesments in Psychiatry. In: Fatemi SH, Clayton PJ, Editors, The Medical Basis of Psychiatry.. Totowa, NJ: Humana Press. 2008; 535-546

(47) Lincoln J, Preskorn SH. Treatment of Depressive Disorders in Elderly Complicated with Medical Co-morbidities and Multiple Medication Use. In: Herrman H, Santorius N, Editors. Depressive Disorders, M.M. John Wiley & Sons, Ltd.: Hoboken, NJ. 2009; 268-270

(48) D'Empaire I, Preskorn SH. New Evidence and Caution. In: Herrman H, Santorius N, Editors. Depressive Disorders, M.M. John Wiley & Sons, Ltd. Hoboken, NJ. 2009; 86-87

Books:

(1) Balderessarini R, Cole J, David J, Gardos G, Preskorn SH, Simpson G et al. Tardive dyskinesia: A task force report. Am J Psychiatry 1980; 137(10):1163-1172.

(2) Janicak P, Davis J, Preskorn SH, Ayd Jr. F. Principles and Practice of Psychopharmacotherapy. 1st

ed. Baltimore: Williams & Wilkins, 1993.

(3) Preskorn SH. Outpatient management of depression. 1st

ed. Caddo, Oklahoma: Professional Communications, Inc., 1994.

(4) Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. 1st

ed. Caddo, OK.: Professional Communications, Inc., 1996.

(5) Janicak P, Davis JM, Preskorn SH, Ayd Jr FJ. Principles and practice of psychopharmacotherapy. 2nd

ed. Baltimore: Williams & Wilkins, 1997.

(6) Preskorn SH. Outpatient Management of Depression. 2nd

ed. Caddo: Professional Communications, Inc., 1999.

(7) Janicak P, Davis JM, Preskorn SH, Ayd Jr. FJ. Principles and Practices of Psychopharmacotherapy. 3rd

ed. Philadelphia: Lippincott Williams and Wilkins, 2001: 369-381.

(8) Preskorn SH, Feighner JP, Stanga CY, Ross R. Handbook of Experimental Pharmacology Antidepressants: Past, Present, and Future. Heidelberg: Springer-Verlag, 2004.

(9) Preskorn SH, Flockhart DA. Psychotropic drug Interactions Guide. New York: MBL Communications, 2004.

(10) Janicak PG, Davis JM, Preskorn SH, Ayd FJ, Jr., Marder SR, Pavuluri MN. Principles and practice of psychopharmacology. 4

th ed. Philadelphia: Lippincott Williams & Wilkins; 2006

(11) Preskorn SH. Outpatient Management of Depression. 3rd

ed. Caddo: Professional Communications, Inc., 2009.

Abstracts:

(1) Preskorn SH, Lewis G. Acetylcholine: General cortical activity vs. stimulus-response. Proceedings of Kansas Psychological Society 14[25]. 1970.

2211

(2) Lewis G, Preskorn SH, Hughes C. The effect of electrical brain stimulation during early development on biochemical and behavioral measures later in life. Proceedings of Southwest Psychological Association 12, 270. 1971.

(3) Preskorn SH, Edwards WD. Microwave fever and experimental sarcoma in mice. Clinical Research 22, 673A. 1974.

(4) Watanabe I, Preskorn SH, Matovich V, Rengarchary S, Sato T. Demyelinating changes in the Schmidt-Lanternman cleft. J Neuropathol Exp Neurol 34, 103. 1975.

(5) Preskorn SH, Kepes J, Bopp W, Watanabe I. Propagation of JC virus in glial cells in PML. Proceedings of the Electron Microscopic Society of America 33, 328. 1975.

(6) Preskorn SH, Denner L. Benzodiazepines sudden withdrawal can elicit psychotic reaction. Modern Medicine 30, 83. 1977.

(7) Preskorn SH, Clark H, Hartman B, Raichle M. Amitriptyline-induced alaterations in cerebral capillary permeability. Society for Neuroscience Abstracts 4, 500. 1978.

(8) Hughes C, Preskorn SH, Hartman B, Veit P. Comparison of behavioral effects of 6-hydroxydopamine, reserpine and terabenzamine. Society for Neuroscience Abstracts 5, 649. 1979.

(9) Preskorn SH, Alward P. The effect of amitriptyline on brain ethanol concentrations. Society of Neuroscience Abstracts 5, 659. 1979.

(10) Irwin G, Preskorn SH. Simultaneous measurement of brain permeability and blood flow in the rat. Society for Neuroscience Abstracts 6, 829. 1980.

(11) Cantilena JrLR, Irwin G, Preskorn SH, Klassen CD. The effect of diethyldithiocarbamate on brain uptake of cadmium. Toxicol Appl Pharmacol 1982; 63(3):338-343.

(12) Preskorn SH, Hartman B, Hughes C, Clark H, Irwin G. 6-Hydroxydopamine ablation of amitriptyline-induced alteration in blood-brain barrier. Society for Neuroscience Abstracts 6, 831. 1980.

(13) Kent T, Preskorn SH. Tetrabenzamine model of depression: Changes in cerebral fluid dynamics. Society for Neuroscience Abstracts 7, 512. 1981.

(14) Winsky R, Preskorn SH, Glotzbach R, Irwin G. Novel antidepressants and neuroleptics: Effect on the central adrenergic system. Society for Neuroscience Abstracts 7, 644. 1981.

(15) Solnik J, Kent T, Preskorn SH, Irwin G. Biogenic amine depletion alter cerebromicrocirculation. Society for Neuroscience Abstracts 8, 850. 1982.

(16) Weller E, Weler R, Preskorn SH. Plasma imipramine levels and clinical response in depressed children. Clin Pharmacol Ther 31, 280. 1982.

(17) Irwin G, Stewart D, Reimold M, Crumpacker J, Kruse M, Preskorn SH. Blood-brain barrier permeability to water measured by a dual-isotope, single transit technique: Effect of altered plasma osmolality. Society for Neuroscience Abstracts 8, 849. 1982.

(18) Weller E, Preskorn SH, Weller R. Childhood depression: Imipramine levels and response. Clin Pharmacol Ther 31, 280. 1982.

(19) Weller R, Glotzbach R, Preskorn SH. Brain concentrations of tricyclic antidepressants: Kinetics and dynamics. Clinical Research 30, 814A. 1982.

(20) Preskorn SH, Othmer S, Lai C, Othmer E, Kent T. EEG abnormalities due to high antidepressant level. Clin Pharmacol Ther 33, 242. 1983.

(21) Weller E, Weller R, Glotzbach E, Preskorn SH. Plasma levels of imipramine and adverse effects in children. Clin Pharmacol Ther 33, 247. 1983.

(22) Hughes C, Kent T, Campbell J, Preskorn SH. Effects of inescapable shock on cerebral blood flow and cerebrovascular permeability in rats. Society for Neuroscience Abstracts 9, 562. 1983.

(23) Swartzman J, Preskorn SH, Kent T, Goldberg S, Glotzbach E. Effects of different classes of psychopharmaceuticals on cerebral capillary permeability and blood flow. Society for Neuroscience Abstracts 9, 157. 1983.

(24) Kent T, Nagy G, Oke A, Preskorn SH, Adams R. Modification of brain extracellular space by CO2: Neural regulation. Society for Neuroscience Abstracts 9, 887. 1983.

(25) Oke A, Kent T, Preskorn SH, Adams R. In vivo electrochemical detection of the effects of CO2 on biogenic amine release. Society for Neuroscience Abstracts 9, 1002. 1983.

2222

(26) Preskorn SH, Bupp SJ, Croskell M, Croskell H. Battleboro rats demonstrate normal cerebromicrocirculatory responsivity to alteration inarterial CO2. Society for Neuroscience Abstracts 13, 773. 1987.

(27) Preskorn SH, Dorey RC, Jerkovich GS, Widener PK. Tricyclic antidepressants: Therapeutic drug monitoring. MIND 2[5], 8-10. 1988.

(28) Preskorn SH. Central nervous system toxicity of tricyclic antidepressants: A case report. MIND 5[2], 7. 1988.

(29) Drevets WC, Raichle ME, Fox PT, Preskorn SH, Videan TO. Trait and state cerebral blood flow abnormalities in depression. Society for Neuroscience Abstracts 15[1], 30. 1989.

(30) Preskorn SH, Swartman J. Mianserin alters cerebromicrocirculatory responsivity to changes in arterial CO2. Society for Neuroscience Abstracts 15, 1220. 1989.

(31) Preskorn SH, Watanabe I, Dick A, Henson SR. Amitriptyline effect on brain fluid dynamics. Society for Neuroscience Abstracts 15, 1220. 1989.

(32) Horst WD, Stucky C, Widener P, Castellani S, Preskorn SH. Evaluation of a receptor binding assay for determining anticholinergic drug levels in plasma. Society for Neuroscience Abstracts 15, 1236. 1989.

(33) Goldstein E, Preskorn SH, Silkey B, Haug L. A comparison of chronic schizophrenics with interictal psychosis. Society for Neuroscience Abstracts 16, 876. 1990.

(34) Cranford J, Goldstein E, Preskorn SH, Moore C. Effects of temporal lobe lesions on the precedence effect in sound localization. Society for Neuroscience Abstracts 16, 1350. 1990.

(35) Preskorn SH. Therapeutic drug monitoring of antidepressants in practice. Clinical Neuropharmacology 13(2), 565. 1990.

(36) Preskorn SH. Cardiovascular and central nervous system toxicity of antidepressants. Clinical Neuropharmacology 15[suppl 1, Part A], 290A-291A. 1992.

(37) Preskorn SH, von Moltke L, Chung M, Messig M, Alderman J, Greenblatt DJ et al. Interaction between fluoxetine or sertraline and desipramine, in vitro and in vivo evaluation in human tissue and subjects. Psychopharmacol Bull 30(1), 121. 1994.

(38) Preskorn SH. Pharmacotherapeutic profile of venlafaxine. Eur Neuropsychopharmacol 5(3), 251-252. 1995.

(39) Preskorn SH. Tandospirone: A viewpoint. CNS Drugs 1996; 5(2):154.

(40) Preskorn SH, Harvey AT. Biochemical and clinical dose-response curves with sertraline. Clin Pharmacol Ther 59[2], 180. 1996.

(41) Preskorn SH. Pharmacology and the relevance for choice. Eur Neuropsychopharmacol 6[S4], 63. 1996.

(42) Harvey AT, Preskorn SH. Mechanism of action of venlafaxine in normal male volunteers. Clin Pharmacol Ther 61[2], 175. 1997.

(43) Preskorn SH, Shad MU, Alderman J, Lane R. Fluoxetine: Age and dose dependent pharmacokinetics and CYP 2C19 inhibition. Clinical Pharmacol Ther 63[2], 166. 1998.

(44) Shad MU, Preskorn SH, Miceli J, Wilner K. Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients. Clin Pharmacol Ther 65, 171. 1999.

(45) Shad MU, Carmichael CA, Preskorn SH, Horst WD. The nature and extent of polypharmacy in patients on antidepressants as a function of treatment setting. Clin Pharmacol Ther 65, 183. 1999.

(46) Preskorn SH. Pharmacogenetic research in clinical psychopharmacology: Design and methodological challenges. Int'l J Neuropsychopharmacology 3[suppl 1], S5. 2000.

(47) Silkey B, Preskorn SH, Golbeck A, Horst WD. Addressing health risks/costs associated with multiple medication use in a veterans integrated service network. 2000. Drug Information Association 2nd Annual Workshop on "Pharmaceutical Outcomes Research".

(48) Silkey B, Preskorn SH, Golbeck A. Interindividual variability in steady-state plasma levels of bupropion and its major metabolites. 2000. 40th Annual NCDEU.

(49) Harvey AT, Preskorn SH. The influence of extended-release venlafaxine on QT intervals of normal volunteers. 2001. 41st

NCDEU

2233

(50) Khan AY, Friesen S, Klick-Davis A, Preskorn SH. How inclusion and exclusion criteria affect the ability to randomize patients in a clinical trial for schizophrenia/schizo-affective disorder. 2001. 41

st NCDEU, Phoenix, AZ.

(51) Preskorn SH, Baker B. The clinical pharmacology of antidepressants: Relevance to the optimum management of the depressed patient. AANP . 2001.

(52) Harvey AT, Preskorn SH. The influence of intramuscular (IM) haloperidol (HAL) or lorazepam (LOR) on QT intervals of volunteers with schizophrenia. Clin Pharm and Ther 71[2], P53. 2002

(53) Preskorn SH, Silkey B, Shah R, Neff M. Multiple medication use and cytochrome P-450 based drug interaction patterns in patients on antidepressants in a regional veterans affairs health care network. Clin Pharm Ther 71[2], 59. 2002

(54) Wesnes,K.A., Preskorn,S.H., Friesen,S., Edgar,C., and Mikkelson,B.O. NS 2330 enhances cognitive function in normal volunteers and volunteers with possible Alzheimer's Disease (AD). Clin Pharm Ther 71:17. 2002

(55) Khan AY, Preskorn SH. Pharmacokinetic principles and drug interactions. Handbook of medical psychiatry. 945-944. 2003

(56) Preskorn SH, Shah R, Silkey B, Neff M, Golbeck A, Choi J. The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline. Clin Pharm Ther 75[2], 71. 2004.

(57) Preskorn SH. Comorbidity polypharmacy and CYP enzymes: What have we learned in terms of safety. World J Biol Psychiatry 5 [suppl 1]:32. 2004

(58) Preskorn SH, Baker B, Klick-Davis A et al. The effect of duloxetine, escitalopram, and sertraline on CYP 2D6 function. Clin Pharm Ther 79(2):52. 2006

(59) Preskorn SH, Lombardo I, Alderman J, Wilner K., Miceli J. Effect of Food on Absorption of Ziprasidone. Clinical Pharmacology & Therapeutics 81:S82. 2007

(60) Ong VS, Deng C, Murray M, Lowe D, Kittrelle J, Preskorn SH. Lack of Hemodynamic Effect of MEM 1003, A Dihydropyridine Calcium-Channel Blocker: An Exposure-Safety Relationship Assessment. Clinical Pharmacology & Therapeutics 81:S64. 2007

(61) Preskorn SH, Patroneva A, et al. A comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine succinate in healthy subjects. The Journal of the European College of Neuropsychopharmacology 17(4): S339. 2007

(62) Preskorn S, Chapel S, et al. Effect of asenapine versus quentiapine and placebo on QTc interval in patients with schizophrenia. The Journal of the European College of Neuropsychopharmacology 17 (4): S453-454. 2007.

(63) Preskorn S, Lombardo I, et al. Effect of meal size and fat content on oral ziprasidone absorption. The Journal of the European College of Neuropsychopharmacology 17 (4): S463-464. 2007

Letters to the Editor:

(1) Preskorn SH, Biggs JT. Use of tricyclic antidepressant blood levels. N Engl J Med 1978; 298(3):166.

(2) Preskorn SH, Madakasira S. Drug monitoring and improved treatment response. Am J Psychiatry 1980; 137(12):1622-1623.

(3) Preskorn SH. A flawed design. J Clin Psychiatry 1982; 43:389-390.

(4) Preskorn SH. Use of plasma levels to avoid amitriptyline toxicity. J Clin Psychiatry 1983; 44(11):430.

(5) Jerkovich G, Preskorn SH. Failure of buspirone to protect against lorazepam withdrawal symptoms. JAMA 1987; 258(2):204-205.

(6) Preskorn SH, Weller E, Hughes C, Weller R. Relationship of plasma imipramine levels to CNS toxicity in children. Am J Psychiatry 1988; 145(7):897.

(7) Goldman D, Katz S, Preskorn SH. What to do about extremely high plasma levels of tricyclics? Am J Psychiatry 1989; 146(3):401-402.

(8) Hon D, Preskorn SH. Mania during fluoxetine treatment for recurrent depression. Am J Psychiatry 1989; 146(12):1638-1639.

(9) Goldstein E, Preskorn SH. Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder. Am J Psychiatry 1989; 146(8):1076-1077.

2244

(10) Preskorn SH, Beber JH, Faul JC, Hirschfeld RMA. Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry 1990; 147(4):532.

(11) Preskorn SH, Fleck R, Schroeder D. Therapeutic drug monitoring of bupropion. Am J Psychiatry 1990; 147(12):1690.

(12) Preskorn SH, Fast GA. Drs. Preskorn and Fast reply. J Clin Psychiatry 1993; 54(5):201-202.

(13) Preskorn SH. Therapeutic drug monitoring with tricyclic antidepressants: A response. J Clin Psychopharmacol 1994; 14, No. 4.

(14) Burke M, Preskorn SH. Sertraline and hepatic metabolism. Consultant Pharmacists 1994; 9:837.

(15) Harvey AT, Preskorn SH. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry 1995; 52:783-784.

(16) Lacey R, Preskorn SH, Jerkovich G. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics? Am J Psychiatry 1995; 152(9):1401.

(17) Preskorn SH. Drug-drug interactions. J Clin Psychiatry 1996; 57(5):223-225.

(18) Burke M, Harvey AT, Preskorn SH. Pharmacokinetics of the newer antidepressants. Am J Med 1996; 100:119-120.

(19) Preskorn SH, Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA 1997; 277(21):682.

(20) Shad MU, Preskorn SH. A possible bupropion and imipramine interaction. J Clin Psychopharmacol 1997; 17(2):118-119.

(21) Shad MU, Preskorn SH. Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome. J Clin Psychopharmacol 1998; 18(4):346-347.

(22) Shad MU. Drug-drug interaction in reverse: Possible loss of phenytoin efficacy as a result of fluoxetine discontinuation. J Clin Pharmacol 1999; 19(5):471-472.

(23) Shad MU, Preskorn SH, Izgur Z. Failure to consider drug-drug interactions as a likely cause of behavioral deterioration in a patient with bipolar disorder. J Clin Psychiatry 2000; 20(3):390-392.

(24) Khan AY, Shad MU, Preskorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. J Clin Psychiatry 2000; 61(7):526-527.

(25) Preskorn SH, Greenblatt DJ, Harvey AT. Lack of effect of sertraline on the pharmacokinetics of alprazolam. Journal of Clinical Psychopharmacology 2000; 20(5):585-586.

(26) Khan AY, Preskorn SH. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. J Clin Psychiatry 2001; 62(5):375-376.

EDITOR OF JOURNAL SUPPLEMENTS:

(1) Clinical crossfire: Pharmacokinetics and psychiatric drugs. Journal of Clinical Psychiatry, 54(suppl), 1993.

(2) Factors to consider in selecting an antidepressant. J of Clinical Psychiatry, 55 (SupA) 1994

(3) Interaction Profile of Sertraline with commonly prescribed medications. Journal of Clinical Psychiatry, 57(suppl 1), 1996.

(4) Sertraline: A pharmacokinetic profile. Journal of Clinical Pharmacokinetics. 32(S1), 1997

EDITOR NPL Facts Newsletter:

(1) Preskorn SH. The laboratory in psychiatry: Monitoring tricyclic antidepressants:An introduction. NPL Facts Newsletter 1990; 1(1):1-4.

(2) Preskorn SH. The laboratory in psychiatry: Monitoring tricylic antidepressants:Avoiding CNS toxicity. NPL Facts Newsletter 1990; 1(2):1-4.

(3) Preskorn SH, Fast GA. The laboratory in psychiatry: monitoring tricylic antidepressants: avoiding cardiac toxicity. NPL Facts Newsletter 1991; 1(3):1-5.

(4) Preskorn SH, Fast F. The laboratory in psychiatry: monitoring tricyclic antidepressants: improving antidepressant efficacy and cost effectiveness. NPL Facts Newsletter 1991; 1(4):1-5.

(5) Preskorn SH. Therapeutic drug monitoring of bupropion and its metabolites: a way of increasing the drug's safe and effective use? NPL Facts Newsletter 1992; 1(5):1-4.

(6) Preskorn SH. Pharmacokinetics and good clinical practice: basic principles. NPL Facts Newsletter 1993; 1(7):1-4.

2255

Published Interviews:

(1) Preskorn SH. An approach to therapeutic drug monitoring (published interview). Currents in Affective illness 1988; 7(10):5-13.

(2) Preskorn SH. Tricyclic antidepressants: The whys and hows of therapeutic drug monitoring. J Clin Psychiatry 1989; 50[suppl 7]:34-42.

(3) Preskorn SH. Selected topics on the pharmacokinetics and drug interactions of selective-serotonin reuptake inhibitors. Currents in Affective illness 1992; 11(2):5-12.

(4) Preskorn SH. Hidden treasure. Schneidler K, editor. Wichita Eagle . 5-13-1996. Wichita.

(5) Preskorn SH. Men's Journal. 86-87. 1996. Jannot,M.

(6) Preskorn SH. Drug interactions with SSRIs: Are they a concern? Curr Issues Depression . 1996. St. Leonards.

(7) Preskorn SH. Pharmacokinetic interactivity of psychotropic drugs: Part I. Rosenblatt JE, Rosenblatt NC, editors. Curr Affect Illness 17[4]. 1998.

(8) Preskorn SH. Pharmacokinetic interactivity of psychotropic drugs: Conclusion. Rosenblatt JE, Rosenblatt NC, editors. Curr Affect Illness 17[5]. 1998.

(9) Preskorn SH. New paradigms for drug development: Part I. Curr in Affective illness 2001; 20(3):5-15.

(10) Preskorn SH. New paradigms for drug development: Part 2. Curr in Affective illness 2001; 20(4):5-15.

(11) Preskorn SH. Polypharmacy of psychotropic drugs. PAREXEL, editor. Ment Health Issues Today 6[3]. 2003. Cenreville.

PSYCHIATRY VIDEOTAPES:

1. Preskorn SH. Antipsychotics. 55 minutes, 1986.

2. Preskorn SH. Antidepressants. 55 minutes, 1986.

3. Preskorn SH. Benzodiazepines. 55 minutes, 1986.

4. Preskorn SH. Benzodiazepines: Abuse and withdrawal liabilities. 30 minutes, 1986.

5. Podrebara F, Preskorn SH. The mental status examination,55 minutes. 1987.

6. Henson S, Preskorn SH. Bipolar disorder: Before and after treatment. 37 minutes, 1988.

7. Henson S, Preskorn SH. Antisocial personality disorder/somatization disorder. 35 minutes, 1989.

8. Preskorn SH. Antidepressants, revised, 55 minutes, 1990.

9. Crisp-Lindgren N, Preskorn SH. Positive and negative symptoms of schizophrenia: Case examples. 37 minutes, 1990.

10. Preskorn SH. Masques of melanacholia: An evening of drama and literature. A clinical discussion of issues involving the diagnosis and treatment of depression. 1992.

11. Rains J, Preskorn SH. The young mania rating scale. 1993.

12. Preskorn SH. Clinical crossfire: Pharmacokinetics and psychiatric drugs. 19 minutes. 1993.

13. Koch J, Preskorn SH. Memory loss and aging: Is it Alzheimer's? 1 hour 54 minutes. 1994.

14. Preskorn SH. Clinical crossfire: Pharmacokinetics and psychiatric drugs. 19 minutes. 1993.

15. Koch J, Preskorn SH. Memory loss and aging: Is it Alzheimer's. 1 hour 54 minutes. 1994.

16. Preskorn SH. Pharmacodetectives: Case histories of antidepressant therapy. 23 minutes. 1995.

17. Preskorn SH. Clinical importance of the cytochrome P450 system in psychiatry. 22 minutes. 1995

18. Preskorn SH. Issues in primary care drug interactions and treatment of depression. 1996.

19. Preskorn SH. Selegiline patch depression with Sahar El-Hodiri. 1997

SLIDE KITS:

1. Preskorn S: Antidpressant update: Pharmacokinetic's, pharmacology, and clinical experience. The Medicine Group, Toronto, 1994.

2266

2. Preskorn S: Advances in antidepressant therapy: The pharmacological basis. Professional Communications, Inc., Caddo, 1994.

3. Preskorn S: The clinically relevant pharmacology of the SSRIs: Pharmacology and Pharmacokinetics, 1994.

4. Preskorn S: Pharmacokinetics and psychiatric medicine: Optimizing efficacy, safety, and cost effectiveness. Current Medical Directions, New York, 1997.

PUBLIC AFFAIRS:

1. Medical Advisor, "The Kansas Mental Illness Test," a prime time one hour television program for Mental Illness Awareness Week, 1989.

2. Medical Advisor, "Beating the Blues," a week long television news series for Mental Illness Awareness Week, 1990.

3. Medical Advisor, "The facts and faces of mental illness: A mental health brochure for the 1990s," developed in conjunction with Roerig-Pfizer Pharmaceutical Co. and distributed state-wide for Mental Illness Awareness Week, 1990.

4. “Live at Five”. An interview on prime time one-hour television program for Mental Awareness Week, 1996.

5. “Mike and Mogie Show”. An interview on prime time television, re: Childhood and Adolescent Depression, April, 1996.

6. “Opinion Newsletter”. An interview for psychiatrists abroad, re: Challenges in the pharmacologic treatment of depression. 1996.

7. Preskorn S: Alzheimer's vascular dementia. KSNW-3, noon call in. October 14, 1996

8. “Live at Five”. An interview on prime time television concerning depression in general, November, 1997.

9. “Family Health Channel, Focus on Depression.” An interview concerning depression, 1998.

SSPPEECCIIAALL PPRREESSEENNTTAATTIIOONNSS::

11.. 11999977-- UUnniivveerrssiittyy ooff TToorroonnttoo iinn TToorroonnttoo,, OOnnttaarriioo,, CCaannaaddaa

22.. VViissiittiinngg PPrrooffeessssoorr ffoorr AAnnnnuuaall PPssyycchhoopphhaarrmmaaccoollooggyy DDaayy::

33.. 11999999-- UUnniivveerrssiittyy ooff HHaammiillttoonn iinn HHaammiillttoonn,, OOnnttaarriioo,, CCaannaaddaa

44.. 11999988-- UUnniivveerrssiittyy ooff AAllbbeerrttaa iinn EEddmmoonnttoonn,, AAllbbeerrttaa,, CCaannaaddaa

5. Sept. 14, 2002 – German Neuroscience Academy in Versailles, France. “Drug development in psychiatry and the human genome project: Implications for clinical practice.”

66.. OOcctt.. 66,, 22000022 –– KKeeyynnoottee aaddddrreessss aatt AAnnnnuuaall PPssyycchhoopphhaarrmmaaccoollooggyy UUppddaattee PPrrooggrraamm ffoorr tthhee UUnniivveerrssiittyy ooff MMiissssiissssiippppii iinn

JJaacckkssoonnvviillllee,, MMSS.. ““TThhee rraattiioonnaall bbaassiiss ffoorr tthhee ccoommbbiinneedd uussee ooff mmoorree tthhaann oonnee ppssyycchhiiaattrriicc mmeeddiiccaattiioonn..””

77.. OOcctt.. 22,, 22000022 –– KKeeyynnoottee aaddddrreessss aatt AAnnnnuuaall PPssyycchhoopphhaarrmmaaccoollooggyy UUppddaattee PPrrooggrraamm ffoorr tthhee UUnniivveerrssiittyy ooff OOkkllaahhoommaa aatt

TTuullssaa.. ““DDrruugg--ddrruugg iinntteerraaccttiioonnss:: TThheeiirr mmeecchhaanniissmmss,, tthheeiirr cclliinniiccaall pprreesseennttaattiioonn,, aanndd tthheeiirr cclliinniiccaall rreelleevvaannccee..””

88.. NNoovv.. 119,, 22000099 -- VViissiittiinngg PPrrooffeessssoorr aatt UUnniivveerrssiittyy ooff TToorroonnttoo GGeenneerraall HHoossppiittaa